coll – -Translation – Keybot Dictionary

Spacer TTN Translation Network TTN TTN Login Deutsch Français Spacer Help
Source Languages Target Languages
Keybot 52 Results  www.pmprb-cepmb.gc.ca
  Crestor  
Show textShow cached sourceOpen source URL
Stein E, Strutt KL, Miller E. ZD4522 is superior to atorvastatin in the treatment of patients with heterozygous familial hypercholesterolemia. J Am Coll Cardiol 2001;37 (suppl A):292. (document papier)
Compare text pagesCompare HTM pagesOpen source URLOpen target URLDefine pmprb-cepmb.gc.ca as primary domain
Stein E, Strutt KL, Miller E. ZD4522 is superior to atorvastatin in the treatment of patients with heterozygous familial hypercholesterolemia. J Am Coll Cardiol 2001;37 (suppl A):292. (hard copy)
  Quoi de neuf  
Show textShow cached sourceOpen source URL
Des études antérieures ont montré des exemples de différences significatives entre la DDD et la dose quotidienne prescrite dans certains groupes de médicaments et de populations (voir Muller et coll., 2006; Dalton et coll., 2007).
Compare text pagesCompare HTM pagesOpen source URLOpen target URLDefine pmprb-cepmb.gc.ca as primary domain
Past studies (see Muller et al. 2006; Dalton et al. 2007) have identified examples of significant differences between the DDD and the prescribed daily dose in selected groups of drugs and populations. It is not the purpose of this study to evaluate the extent to which the DDD may or may not reflect the utilization patterns observed in Canadian administrative databases. However, some examples of significant disparities are provided in this section along with an indication of the implications of such disparities on the interpretation of Canadian drug utilization and costs.
  L'Observateur des médic...  
Show textShow cached sourceOpen source URL
19 OLSON, J.J., N.A. PALEOLOGOS, L.E. GASPAR et coll. « The role of emerging and investigational therapies for metastatic brain tumors: a systematic review and evidence-based clinical practice guideline of selected topics », J Neurooncol.
Compare text pagesCompare HTM pagesOpen source URLOpen target URLDefine pmprb-cepmb.gc.ca as primary domain
19 Olson JJ, Paleologos NA, Gaspar LE, et al. The role of emerging and investigational therapies for metastatic brain tumors: a systematic review and evidence-based clinical practice guideline of selected topics. J Neurooncol. 2010; 96(1):115–42.
  Quoi de neuf  
Show textShow cached sourceOpen source URL
Des études antérieures ont montré des exemples de différences significatives entre la DDD et la dose quotidienne prescrite dans certains groupes de médicaments et de populations (voir Muller et coll., 2006; Dalton et coll., 2007).
Compare text pagesCompare HTM pagesOpen source URLOpen target URLDefine pmprb-cepmb.gc.ca as primary domain
Past studies (see Muller et al. 2006; Dalton et al. 2007) have identified examples of significant differences between the DDD and the prescribed daily dose in selected groups of drugs and populations. It is not the purpose of this study to evaluate the extent to which the DDD may or may not reflect the utilization patterns observed in Canadian administrative databases. However, some examples of significant disparities are provided in this section along with an indication of the implications of such disparities on the interpretation of Canadian drug utilization and costs.
  L'Observateur des médic...  
Show textShow cached sourceOpen source URL
4 STEG, P.G., S. JAMES, R.A. HARRINGTON, D. ARDISSINO et coll. « Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis », Circulation, vol. 122, no 21 (2010), p.
Compare text pagesCompare HTM pagesOpen source URLOpen target URLDefine pmprb-cepmb.gc.ca as primary domain
4 Steg PG, James S, Harrington RA, Ardissino D, et al. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation. 2010; 122(21):2131–41.
  L'Observateur des médic...  
Show textShow cached sourceOpen source URL
16 STERNBERG, C.N., D.P. PETRYLAK, O. SARTOR et coll. « Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial », J Clin Oncol.
Compare text pagesCompare HTM pagesOpen source URLOpen target URLDefine pmprb-cepmb.gc.ca as primary domain
16 Sternberg CN, Petrylak DP, Sartor O, et al. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol. 2009; 27(32):5431–8.
  Quoi de neuf  
Show textShow cached sourceOpen source URL
Même si elle ne concerne pas les statines, ni le nombre de jours d’approvisionnement en particulier, une évaluation de l’exactitude des données administratives sur les demandes de remboursement de médicaments dans la base de données du PMO a été effectuée (Levy et coll., 2003).
Compare text pagesCompare HTM pagesOpen source URLOpen target URLDefine pmprb-cepmb.gc.ca as primary domain
Although not specific to the statins, nor the days supplied information, the coding accuracy of administrative drug claims in the ODB database has been assessed ( Levy et al. 2003). According to the assessment, pharmacists almost always dispensed the medication that was prescribed and the information was reliably submitted to the ODB drug claims database. Thus, conclusions drawn by researchers using these data are not likely to be compromised by the reliability of the coding.
  L'utilisation de bandel...  
Show textShow cached sourceOpen source URL
GOMES et coll. « Blood glucose test strips: options to reduce usage »,
Compare text pagesCompare HTM pagesOpen source URLOpen target URLDefine pmprb-cepmb.gc.ca as primary domain
. Canadian Medical Association Journal. 2010; 182(1): 28–34.17
  L'utilisation de bandel...  
Show textShow cached sourceOpen source URL
19 MALANDA et coll.
Compare text pagesCompare HTM pagesOpen source URLOpen target URLDefine pmprb-cepmb.gc.ca as primary domain
19 Malanda et al.
  Quoi de neuf  
Show textShow cached sourceOpen source URL
Même si l’objectif de l’OMS est de maintenir la stabilité du système ATC/DDD, des changements se produisent tout de même. Les études dans lesquelles la méthodologie de la DDD est appliquée ne font pas toujours allusion aux valeurs des DDD ni à la version du système ATC/DDD (voir Ronning et coll., 2000).
Compare text pagesCompare HTM pagesOpen source URLOpen target URLDefine pmprb-cepmb.gc.ca as primary domain
Although it is the intention of the WHO to maintain a stable ATC/DDD system, changes do occur. Studies applying the DDD methodology do not always reference the DDD values or the ATC/DDD edition used (see Ronning et al. 2000). This makes it difficult to compare results across studies, as the DDD assignment may differ from one edition to another. Studies applying the DDD methodology should properly indicate the WHO ATC/DDD edition used (Ronning 2001).
  L'Observateur des médic...  
Show textShow cached sourceOpen source URL
5 McHUTCHISON, J.G., M.P. MANNS, A.J. MUIR et coll.; PROVE3 Study Team. « Telaprevir for previously treated chronic HCV infection », N Engl J Med, vol. 362, no 14 (2010), p. 1292-1303.
Compare text pagesCompare HTM pagesOpen source URLOpen target URLDefine pmprb-cepmb.gc.ca as primary domain
5 McHutchison JG, Manns MP, Muir AJ, et al; PROVE3 Study Team. Telaprevir for previously treated chronic HCV infection. N Engl J Med. 2010; 362(14):1292–303.
  Quoi de neuf  
Show textShow cached sourceOpen source URL
La méthodologie de la DDD peut être utilisée pour effectuer des prévisions, par exemple, sur le coût par dose dans le traitement des données manquantes ou erronées dans un ensemble de données (Lummis et coll., 2008).
Compare text pagesCompare HTM pagesOpen source URLOpen target URLDefine pmprb-cepmb.gc.ca as primary domain
The DDD methodology can be used to make assumptions, for instance, on the cost per dose when dealing with missing or inaccurate data in a dataset (Lummis et al. 2008). However, this application is valid only if the DDD is in line with the RDD or if the results are not likely to be impacted by potential differences between the two measures.
  Quoi de neuf  
Show textShow cached sourceOpen source URL
Les avantages et les limites de l’application de la méthodologie de la DDD dans le cadre des bases de données administratives canadiennes ont été abordés au préalable (Sketris et coll., 2004). Cette section donne un aperçu détaillé de ces avantages et limites à la lumière de l’analyse fournie à la section 2.
Compare text pagesCompare HTM pagesOpen source URLOpen target URLDefine pmprb-cepmb.gc.ca as primary domain
The advantages and limitations of applying the DDD methodology in the context of Canadian administrative databases have been discussed before (Sketris et al. 2004). This section provides a detailed overview of these advantages and limitations in light of the analysis provided in Section 2. Further detailed analysis is provided in Appendix 1.
  Quoi de neuf  
Show textShow cached sourceOpen source URL
La méthode de calcul des coûts moyens par cohorte d’âge–sexe et de multiplication des valeurs par la population prévue visée dans chaque cohorte d’âge–sexe respective a été utilisée dans plusieurs études (Garrett et Martini, 2007; ICIS, 2005; Denton et coll., 2002).
Compare text pagesCompare HTM pagesOpen source URLOpen target URLDefine pmprb-cepmb.gc.ca as primary domain
The methodology is explained in terms of prescription expenditures. Except for the adjustment for inflation, the same methodology was applied to the number of claims. The method of calculating average costs per age–sex cohort and multiplying the values by the projected population of interest in each respective age–sex cohort has been widely used (Garrett and Martini 2007; CIHI 2005; Denton et al. 2002).
  Quoi de neuf  
Show textShow cached sourceOpen source URL
Des études ont été effectuées sur la présentation et la comparaison du coût par DDD pour les médicaments, les groupes de médicaments ou les populations (voir Goel et coll., 1996; Metge et coll., 2003).
Compare text pagesCompare HTM pagesOpen source URLOpen target URLDefine pmprb-cepmb.gc.ca as primary domain
There have been studies that report and compare the cost per DDD for drugs, groups of drugs or populations (see Goel et al. 1996; Metge et al. 2003). If there is agreement between the DDD and the RDD, the cost per DDD can provide a rough idea of the treatment cost. However, if the extent of agreement is unknown, caution should be used when interpreting the results.
  Quoi de neuf  
Show textShow cached sourceOpen source URL
Des études ont été effectuées sur la présentation et la comparaison du coût par DDD pour les médicaments, les groupes de médicaments ou les populations (voir Goel et coll., 1996; Metge et coll., 2003).
Compare text pagesCompare HTM pagesOpen source URLOpen target URLDefine pmprb-cepmb.gc.ca as primary domain
There have been studies that report and compare the cost per DDD for drugs, groups of drugs or populations (see Goel et al. 1996; Metge et al. 2003). If there is agreement between the DDD and the RDD, the cost per DDD can provide a rough idea of the treatment cost. However, if the extent of agreement is unknown, caution should be used when interpreting the results.
  L'Observateur des médic...  
Show textShow cached sourceOpen source URL
7 HODI, F.S., S.J. O´DAY, D.F. McDERMOTT et coll. « Improved survival with ipilimumab in patients with metastatic melanoma », N Engl J Med, vol. 363, no 8 (2010), p. 711-723.
Compare text pagesCompare HTM pagesOpen source URLOpen target URLDefine pmprb-cepmb.gc.ca as primary domain
7 Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363(8):711–23.
  L'Observateur des médic...  
Show textShow cached sourceOpen source URL
17 KANTOFF, P.W., C.S. HIGANO, N.D. SHORE et coll. ; pour IMPACT Study Investigators. « Sipuleucel-T immunotherapy for castration-resistant prostate cancer », N Engl J Med. , vol. 363, no. 5 (2010), p 411-422.
Compare text pagesCompare HTM pagesOpen source URLOpen target URLDefine pmprb-cepmb.gc.ca as primary domain
17 Kantoff PW, Higano CS, Shore ND, et al; for IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010; 363(5):411–22.
  L'Observateur des médic...  
Show textShow cached sourceOpen source URL
6 BRODIE, M.J., H. LERCHE, A. GIL-NAGEL et coll. ; pour RESTORE 2 Study Group. « Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy », Neurology, vol. 75, no 20 (2010), p.
Compare text pagesCompare HTM pagesOpen source URLOpen target URLDefine pmprb-cepmb.gc.ca as primary domain
6 Brodie MJ, Lerche H, Gil-Nagel A, et al; for RESTORE 2 Study Group. Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy. Neurology. 2010; 75(20):1817–24.
  L'Observateur des médic...  
Show textShow cached sourceOpen source URL
14 SPAGNOLO, P, C. DEL GIOVANE, F. LUPPI et coll. « Non-steroid agents for idiopathic fibrose pulmonaire », Cochrane Database Syst Rev., no 9 (2010), CD003134.
Compare text pagesCompare HTM pagesOpen source URLOpen target URLDefine pmprb-cepmb.gc.ca as primary domain
14 Spagnolo P, Del Giovane C, Luppi F, et al. Non-steroid agents for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev. 2010; (9):CD003134.
  TNKase  
Show textShow cached sourceOpen source URL
. Combination reperfusion therapy with epitfibatide and reduced dose tenecteplase for ST-elevation myocardial infarction: results of the integrilin and tenecteplase in acute myocardial infraction (INTEGRITI) phase II angiographic trial. J Am Coll Cardiol 2003;41(8):1251-60.
Compare text pagesCompare HTM pagesOpen source URLOpen target URLDefine pmprb-cepmb.gc.ca as primary domain
Combination reperfusion therapy with epitfibatide and reduced dose tenecteplase for ST-elevation myocardial infarction: results of the integrilin and tenecteplase in acute myocardial infraction (INTEGRITI) phase II angiographic trial. J Am Coll Cardiol 2003;41(8):1251-60.
  Quoi de neuf  
Show textShow cached sourceOpen source URL
Les lignes directrices canadiennes de pratique clinique établies au cours des dix dernières années exigeaient une réduction progressive des taux cibles de lipides chez les patients à haut risque (risque sur 10 ans de coronaropathie de ³ 20 %). En 2003, les lignes directrices recommandaient un taux de cholestérol à lipoprotéines de faible densité de £ 2,5 mmol/L (Genest et coll., 2003) pour les patients à haut risque.
Compare text pagesCompare HTM pagesOpen source URLOpen target URLDefine pmprb-cepmb.gc.ca as primary domain
The Canadian clinical practice guidelines issued during the past decade have called for an increasingly greater reduction in the target lipid levels for high-risk patients (10-year risk of coronary artery disease ³ 20%). In 2003, the guidelines recommended that high-risk patients target a LDL-C level of £ 2.5 mmol/L (Genest et al. 2003). This represented a tighter control level for the group of patients with a 10-year CAD risk in the 20-30% range (the 2000 guidelines recommended a LDL-C target level of £ 3.0 mmol/L (see Fodor et al. 2000)). By 2006, the LDL-C treatment target for high-risk patients was further reduced to £ 2.0 mmol/L (McPherson et al. 2006). These higher target LDL-C values often necessitated increased doses of statins, among other interventions.
  Quoi de neuf  
Show textShow cached sourceOpen source URL
Les lignes directrices canadiennes de pratique clinique établies au cours des dix dernières années exigeaient une réduction progressive des taux cibles de lipides chez les patients à haut risque (risque sur 10 ans de coronaropathie de ³ 20 %). En 2003, les lignes directrices recommandaient un taux de cholestérol à lipoprotéines de faible densité de £ 2,5 mmol/L (Genest et coll., 2003) pour les patients à haut risque.
Compare text pagesCompare HTM pagesOpen source URLOpen target URLDefine pmprb-cepmb.gc.ca as primary domain
The Canadian clinical practice guidelines issued during the past decade have called for an increasingly greater reduction in the target lipid levels for high-risk patients (10-year risk of coronary artery disease ³ 20%). In 2003, the guidelines recommended that high-risk patients target a LDL-C level of £ 2.5 mmol/L (Genest et al. 2003). This represented a tighter control level for the group of patients with a 10-year CAD risk in the 20-30% range (the 2000 guidelines recommended a LDL-C target level of £ 3.0 mmol/L (see Fodor et al. 2000)). By 2006, the LDL-C treatment target for high-risk patients was further reduced to £ 2.0 mmol/L (McPherson et al. 2006). These higher target LDL-C values often necessitated increased doses of statins, among other interventions.
  Quoi de neuf  
Show textShow cached sourceOpen source URL
Les lignes directrices canadiennes de pratique clinique établies au cours des dix dernières années exigeaient une réduction progressive des taux cibles de lipides chez les patients à haut risque (risque sur 10 ans de coronaropathie de ³ 20 %). En 2003, les lignes directrices recommandaient un taux de cholestérol à lipoprotéines de faible densité de £ 2,5 mmol/L (Genest et coll., 2003) pour les patients à haut risque.
Compare text pagesCompare HTM pagesOpen source URLOpen target URLDefine pmprb-cepmb.gc.ca as primary domain
The Canadian clinical practice guidelines issued during the past decade have called for an increasingly greater reduction in the target lipid levels for high-risk patients (10-year risk of coronary artery disease ³ 20%). In 2003, the guidelines recommended that high-risk patients target a LDL-C level of £ 2.5 mmol/L (Genest et al. 2003). This represented a tighter control level for the group of patients with a 10-year CAD risk in the 20-30% range (the 2000 guidelines recommended a LDL-C target level of £ 3.0 mmol/L (see Fodor et al. 2000)). By 2006, the LDL-C treatment target for high-risk patients was further reduced to £ 2.0 mmol/L (McPherson et al. 2006). These higher target LDL-C values often necessitated increased doses of statins, among other interventions.
  L'utilisation de bandel...  
Show textShow cached sourceOpen source URL
Dans une étude menée à l’ACMTS par Cameron et coll.17, les auteurs ont constaté que [
Compare text pagesCompare HTM pagesOpen source URLOpen target URLDefine pmprb-cepmb.gc.ca as primary domain
Note: Values may not add to total or subtotal percentages due to rounding. SMBG, self-monitoring of blood glucose.